<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0346429" disease_type="Neoplastic Process" abbrv="">Multiple cancer</z:e> vaccine trials have been carried out using ex vivo generated autologous dendritic cells (DCs) loaded with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> antigen before readministration into patients </plain></SENT>
<SENT sid="1" pm="."><plain>Though promising, overall immunologic potency and clinical efficacy might be improved with more efficient DC-based therapies that avoid ex vivo manipulations, but are instead based on in vivo targeting of DCs </plain></SENT>
<SENT sid="2" pm="."><plain>For initial in vivo proof of concept studies, we evaluated targeting of proteins or <z:chebi fb="7" ids="16670">peptides</z:chebi> to DCs through DC-specific intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 3-grabbing nonintegrin (DC-SIGN) </plain></SENT>
<SENT sid="3" pm="."><plain>Because the biology of DC-SIGN is different between mice and humans, we assess human DC-SIGN targeting in the setting of elements of a human immune system in a mouse model </plain></SENT>
<SENT sid="4" pm="."><plain>Administration of anti-DC-SIGN antibodies carrying either <z:e sem="disease" ids="C0039614" disease_type="Disease or Syndrome" abbrv="">tetanus</z:e> toxoid <z:chebi fb="7" ids="16670">peptides</z:chebi> or keyhole limpet hemocyanin (KLH) to Rag2gammaC mice reconstituted with human immune cells raised stimulatory human T-cell responses to the respective antigen without additional adjuvant requirements </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, administration of anti-DC-SIGN antibody-KLH conjugate enhanced the adjuvant properties of KLH resulting in inhibition of RAJI (Human Burkitt's <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> Cell Line) cell <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in Nonobese Diabetic/Severe Combined Immunodeficient mice transplanted with human immune cells </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, mouse models reconstituted with human immune cells seem to be suitable for evaluating DC-targeted vaccines, and furthermore, targeting to DCs in situ via DC-SIGN may provide a promising vaccine platform for inducing strong immune responses against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:e sem="disease" ids="C0009450" disease_type="Disease or Syndrome" abbrv="">infectious disease</z:e> agents </plain></SENT>
</text></document>